今天，沪指8连阳，创新药千亿市值龙头股大涨

Group 1 - The A-share market showed divergence with the Shanghai Composite Index rebounding and surpassing 3300 points, marking an 8-day consecutive rise, while the Shenzhen Component and ChiNext Index declined [1] - The logistics, cross-border payment, free trade port, unified market, and diversified finance sectors surged due to the release of two significant policy documents aimed at enhancing the Shanghai International Financial Center [5] - Pharmaceutical stocks rebounded, particularly in the innovative drug sector, with several leading companies reaching historical highs, such as BaiLi TianHeng, which rose by 11.41% to a market capitalization of 116.9 billion [5] Group 2 - Multiple pharmaceutical companies reported positive developments in clinical trials for innovative drugs, including HengRui Medicine's approval for two clinical trials and XinLiTai's acceptance of a clinical trial application for a gene-editing drug [5] - Industry analysis indicates that Chinese innovative drug companies possess significant advantages in research efficiency and cost control, leading to faster drug development and higher potential returns for investors [6] - The consumer sector was active, with retail and duty-free shop stocks rising, highlighted by GuoFang Group hitting the daily limit for the 13th time in 12 trading days [6]